In the search for compounds which decrease plasma lipids in man and animals, gemfibrozil was selected from a series of related compounds synthesized in our laboratories (Creger et al. 1976 ) as having pronounced oral activity in lowering rat, mouse and monkey triglycerides, components of circulating lipoproteins involved in the development of atherosclerosis and heart disease.
Chemically, gemfibrozil is 2,2 dimethyl-5 (2,5 xylyloxy)-valeric acid, also known as 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid. The structures of gemfibrozil and of clofibrate, a known hypolipidwmic agent, are: CH3 CH3 CI--0-C-COOC2H5 CH3 
Methods and Results in Normal Animals
In determining the lipid lowering properties of gemfibrozil as compared with clofibrate, the following methods were employed:
For rats and mice, the compounds were given by oral intubation as a fine suspension ground into 4 % aqueous gum acacia. White male Spartan descendents of Sprague-Dawley rats (200-250 g) , female Spartan rats (175-190 g) or white male Swiss mice (1 5-20 g) were treated daily for seven days. They were fed a normal commercial diet with drinking water ad libitum. Ten animals per group were used for each dose level, and experiments were repeated two to 10 times. At termination, they were lightly anesthetized with ether, and blood was taken from the heart atrium in heparinized syringes. After centrifugation, plasma cholesterol was determined by a modified Abell-Zak method (Mann 1961) and plasma triglycerides by the Leveille method (Leveille et al. 1961 ). In some cases, simultaneous Dr R E Maxwell determination of cholesterol and triglycerides was carried out by the Technicon Auto Analyzer II procedure (Technicon Corporation 1971) . Results were evaluated by Student's t test for significance compared with controls, and all reported values were significant at P<0.05.
The compounds were given orally as a suspension at 50 mg/kg per day (gemfibrozil) or at 100 mg/kg per day (clofibrate) to rhesus monkeys (4 kg), selected to have adequate fasting triglyceride levels with minimum standard deviation in three weekly pretreatment blood samples. The monkeys were fed a normal diet of rice-liver balls supplemented with commercial biscuits. Dosing continued for three weeks, blood samples being taken at weekly intervals. After the drugs were discontinued, samples were taken for an additional two weeks. Table 1 shows the effects of several dose levels of gemfibrozil in rats and mice compared with clofibrate. At high levels in male rats only clofibrate reduced plasma cholesterol, whereas both compounds lowered plasma triglycerides. At lower doses, gemfibrozil continued to reduce triglycerides with 55% reduction at 10 mg/kg, although clofibrate was ineffective at 50 mg/kg. The log-dose response in male rats, as taken from the graph and calculated by the method of least squares, shows that gemfibrozil is at least 15 times more active than clofibrate in reducing plasma triglycerides. Gemfibrozil also lowered triglycerides in female rats at 25 mg/kg, but clofibrate was ineffective at 250 mg/kg. Both compounds reduced triglycerides in mice at 300 mg/kg, although cholesterol was not decreased. Table 2 shows the effects of gemfibrozil on rat liver weight and liver triglycerides (Butler et al. 1961) in three studies with male rats with different dose levels. Liver triglycerides expressed as mg/g of tissue tended to decrease, but with the increased liver weight, total triglycerides remained the same.
Results

Rats and mice:
Levels of cholesterol in heart, aorta, liver, kidney and adrenals were normal at doses of 250 mg/kg of gemfibrozil for seven days. There were no abnormal sterol intermediates accumu-lated in liver, as shown by isolation and gasliquid chromatography (Rodney et al. 1965) .
Monkeys: Table 3 shows the effects of gemfibrozil on monkey plasma triglycerides. At 50 mg/kg there was a decrease of 36-76 % in 3 of 4 monkeys in one week. By three weeks all monkeys had responded (48-75 % decrease). After cessation; of treatment, values returned to pretreatment levels. With clofibrate given daily at 100 mg/kg, triglycerides fell in one week, but returned to normal during treatment at two and three weeks. In 12-week studies with gemfibrozil, triglyceride levels were reduced in 3 monkeys (unselected as to pretreatment values) at four weeks (32-65 %), and in 2 of 3 at 12 weeks (58%) at 300 mg/kg. There was no consistent effect on plasma cholesterol.
Hyperlipaemic rats: Groups of 10 male rats were dosed orally with gemfibrozil at 25 mg/kg or clofibrate at 100 mg/kg for seven days. On the last day, they were given 10% fructose in the drinking water overnight (18 h). This has been shown to elevate plasma triglycerides (Nikkila & Ojala 1966) . Plasma triglyceride analyses showed that gemfibrozil significantly prevented the rise in triglycerides due to this regimen, whereas clofibrate had minimal efrects (Table 4 ). Mechanism ofAction Studies Inhibition of triglyceride synthesis: One possible mechanism of action of gemfibrozil could be the inhibition of the incorporation of fatty acids into triglycerides. In a study of palmitate incorporation, male rats were dosed orally with 25 mg/kg of gemfibrozil for seven days, with the last dose 1 h before i.v. injection of 2 ,uCi/100 g body weight of palmitic [1-14C] acid sodium salt bound to normal rat plasma. Controls were similarly injected. The animals were killed after 30 min (Borgstrom & Olivecrona 1961) and plasma and livers were analysed for triglycerides. The triglyceride radioactivity was counted after separation from other components by thin-layer chromatography (Young & Lynen 1969) .
The results (Table 5) show that gemfibrozil reduced plasma triglyceride levels by 52%, and plasma specific activity was reduced by 37 %. Although liver triglyceride levels per gram were reduced 250%, because of the increase in liver weight the total triglyceride content was not significantly lower. However, the specific activity of liver triglycerides was decreased 29%. The results suggest that gemfibrozil decreased incorporation of palmitate into newly-formed triglycerides, secreted as very low density lipoproteins (VLDL) (Eisenberg & Levy 1975) .
Inhibition of lipolysis: Inhibition of adipose tissue lipolysis has been suggested as a mechanism of action for clofibrate (Barrett & Thorp 1968) . The literature has conflicting reports on in vitro and in vivo studies varying with the system, species, method of analysis and agonists used (Carlson & Walldius 1972 , D'Costa & Angel 1973 . Effects on glycerol release are preferable to free fatty acid release studies, since both clofibric acid and gemfibrozil interfere with fret; fatty acid methods, for which corrections must be applied. Table 6 shows the results of in vitro experiments based on enzymatic analysis (Vaughan 1962 ) of glycerol released from rat adipose tissue. Table 6 Effect of gemfibrozil or clofibric acid on lipolysis4 rat adipose tissue in vitro In one experiment, epididymal adipose tissue from rats fasted for 72 h, and re-fed a high carbohydrate diet for 48 h to stimulate lipolysis, was incubated with or without gemfibrozil (4 x 10-3M) or 104 ,tu of insulin. Results indicate equivalent inhibition of basal lipolysis. In a second experiment, epididymal fat (100 mg) from normal rats was incubated for 2 h in 3 ml of Krebs-Ringer bicarbonate medium pH 7.4 containing 4% bovine albumin, with and without the addition of 5 x 10-4M gemfibrozil or 6 x 10-4M clofibric acid, as sodium salts. Noradrenaline (2 x 10-6M) was added to a second series for stimulation of lipolysis. All incubations were in triplicate.
Results show that both compounds inhibited basal lipolysis 60% and 59% respectively, but had no statistically significant effect on noradrenaline-induced lipolysis. Witiak et al. (1971) have shown that clofibric acid inhibits noradrenalineinduced lipolysis at levels above 10-3M, but inhibits only basal lipolysis at concentrations in the range attainable in vivo.
Effect on selected liver enzymes: Hess et al. (1965) have reported that clofibrate fed to rats increased the specific activity of liver catalase and alphaglycerophosphate dehydrogenase, which may influence triglyceride metabolism. Maragoudakis (1969) reported that clofibrate is an inhibitor of rat liver acetyl Co-A carboxylase, a key enzyme in fatty acid synthesis. We investigated the effect of gemfibrozil on these enzymes (Table 7 ). In rats given 250 mg/kg of gemfibrozil for seven days, there was no increase in the activity of liver homogenate alpha-glycerophosphate dehydrogenase (Lee & Lardy 1965) , whereas clofibrate at 250 mg/kg stimulated activity by 68 %. Catalase, as determined by the method of Creasey (1960) , was not stimulated by either compound under these conditions.
In vitro studies with acetyl Co-A carboxylase prepared from rat liver homogenate (Vagelos et al. 1963 ) and assayed in a system with activatorcitrate, acetyl Co-A and NaH[14C]02 showed that gemfibrozil at 1.9 x 10-3M inhibited the enzyme by 62o%, but livers from rats given the compound at 250 mg/kg for five days did not show decreased acetyl Co-A carboxylase activity.
Other Studies
Gemfibrozil was not oestrogenic in ovariectomized female rats at doses of 25-200 mg/kg, since it did not increase uterine weight. It had no antiinflammatory activity in guinea pigs at 100 mg/ kg, and had no cardiovascular or central nervous system activity. It did not affect glucose tolerance tests in rats. At high doses in rats for two weeks, it had no effect on plasma fibrinogen levels.
Summary
Gemfibrozil is an effective agent in lowering plasma triglycerides in rats, mice and rhesus monkeys. It was about 15 times more effective than clofibrate in reducing triglycerides in male rats. It also reduced triglycerides in rats made hypertriglyceridimic, and was active in female rats, in contrast to a lack of these effects shown by clofibrate. Although it produced some hepatomegaly in rats, as does clofibrate, it did not increase liver lipids nor cause certain enzymatic changes seen with clofibrate. Its mechanism of action is not clear, but in experiments to elucidate such effects it reduced the incorporation of longchain fatty acids into rat liver triglycerides and inhibited basal (but not hormonally induced) lipolysis of rat adipose tissue.
DISCUSSION
Dr A N Howard (Cambridge) commented on the large difference between the effects of clofibrate and gemfibrozil on cholesterol metabolism. He asked whether Dr Maxwell had studied the effect of gemfibrozil on the incorporation of acetate into cholesterol or on bile composition.
Dr Maxwell said that since they had observed no effect on serum cholesterol they had not investigated these possible mechanisms.
Dr R M Hodges (Chairman) said the question will probably be investigated now in human subjects.
Dr G J Galton (London) had investigated the effect of gemfibrozil on acetate incorporation into isoprenoids in human leukocytes. Incorporation was suppressed at a drug concentration of about 1 mM.
Professor V Wynn (London) pointed to a difficulty in animal studies since the animals were not usually hyperlipidcmic. Indeed, the search for a drug with important hypolipidlemic effects, if confined to a human population with normal lipid values, might never have resulted in the discovery of a drug such as clofibrate.
In simple endogenous human hypertriglycerideemia, for example, there were several abnormal mechanisms not seen in the normal human being. There was, for example, an increased free fatty acid flux which was probably the site of action of gemfibrozil as it was for clofibrate. He was not surprised that a hypocholesterolamic effect was not demonstrated in normal subjects. He would have been surprised if it had been. However, clinical studies did show effects in the hyperlipidcmic subject.
Dr R Ylikahri (Helsinki) commented that the effect of gemfibrozil on the liver to body weight ratio was very similar to that of clofibrate. He asked whether gemfibrozil caused electron microscopic changes in the liver similar to those which clofibrate was known to induce. Dr Hodges said that this subject would be fully dealt with when the preclinical toxicology data and electron microscopic studies were discussed in the next session.
Dr V Manninen (Helsinki) commented that both gemfibrozil and clofibrate were very effective in reducing cholesterol and triglyceride values which had been increased by the effects of hypoxia.
